Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial
Chantal Mathieu, Julie Wych, Emile Hendriks, Lisa Van Ryckeghem, Timothy Tree, Piotr Jaroslaw Chmura, C. Møller, Kristina Casteels, Thomas Danne, Felix Reschke, Darja Šmigoc Schweiger, Tadej Battelino, Jesper Johannesen, Birgit Rami‐Merhar, Thomas R. Pieber, Christophe De Block, Mark L. Evans, Robert Hilbrands, Emanuele Bosi, Ruben H. Willemsen, Supriyo Basu, Mari‐Anne Pulkkinen, Mikael Knip, Miriam Cnop, Almut Nitsche, Anke M. Schulte, E. Niemöller, Mark Peakman, Charlotte S. Wilhelm-Benartzi, David Gillespie, Lut Overbergh, Adrian Mander, M. Loredana Marcovecchio, M Loredana Marcovecchio, Chantal Mathieu, Chantal Mathieu, Lutgart Overbergh, Mark Evans, A. Emile J. Hendriks, M. Loredana Marcovecchio, Mark Peakman, Timothy Tree, Noel G. Morgan, John A. Todd, Linda Wicker, Adrian P. Mander, Colin M Dayan, Julie Wych, David Gillespie, Thomas Pieber, Decio L. Eizirik, Miriam Cnop, Søren Brunak, Flemming Pociot, Jesper Johannesen, Roberto Mallone, Mikael Knip, Timo Otonkoski, Riitta Veijola, Riitta Lahesmaa, Anette G. Ziegler, Michele Solimena, Ezio Bonifacio, Reinhard Holl, Francesco Dotta, Francesco Chiarelli, Piero Marchetti, Emanuele Bosi, Stefano Cianfarani, Carine de Beaufort, Knut Dahl-Jørgensen, Przemyslawa Jarosz-Chobot, Tadej Battelino, Martin Gotthardt, Bart O. Roep, Markus Lundgren, Guillaume Costecalde, Matthias von Herrath, Antonella Napolitano-Rosen, Elisabeth Niemöller, Stefanie Keil, Sanjoy Dutta, Esther Latres, Gina Agiostratidou, Anne Koralova